Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes

British Journal of Pharmacology

Volumn 163, Issue 7, 2011, Pages 1479-1494

  De Petrocellis, Luciano ^a   Ligresti, Alessia ^a   Moriello, Aniello Schiano ^a   Allarà, Marco ^a   Bisogno, Tiziana ^a   Petrosino, Stefania ^a   Stott, Colin G ^b   Di Marzo, Vincenzo ^a  

^a CNR   (Italy)

^b Porton Down Science Park   (United Kingdom)

Author keywords

botanical extract; cannabinoids; cannabis; diacylglycerol lipase; endocannabinoid; monoacylglycerol lipase; TRP channel; TRPA1; TRPM8; TRPV1

Indexed keywords

ACYLGLYCEROL LIPASE; ANANDAMIDE; CANNABICHROMENE; CANNABIDIOLIC ACID; CANNABIDIVARIN ACID; CANNABIGEROL; CANNABIGIVARIN; CANNABINOL; CANNABIS DERIVATIVE; DIACYLGLYCEROL LIPASE ALPHA; FATTY ACID AMIDASE; HYDROLASE; LIPOPROTEIN LIPASE; N ACYLETHANOLAMINE ACID AMIDE HYDROLASE; TETRAHYDROCANNABINOLIC ACID; TETRAHYDROCANNABIVARIN; TETRAHYDROCANNABIVARIN ACID; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1; TRANSIENT RECEPTOR POTENTIAL CHANNEL M8; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 2; 2 ARACHIDONOYLGLYCEROL; ALLYL ISOTHIOCYANATE; CALCIUM; CANNABIDIOL; CANNABINOID; CANNABINOID DERIVATIVE; CANNABIS; DRONABINOL; TETRAHYDROCANNABINOL; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL 2;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DETERMINATION; DRUG MECHANISM; DRUG POTENCY; ENZYME ASSAY; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; CALCIUM CELL LEVEL; CELL STRAIN HEK293; CELL TRANSPORT; CONCENTRATION RESPONSE; DRUG EFFICACY; ENZYME DEGRADATION; FLUORESCENCE ANALYSIS; IMMUNOFLUORESCENCE TEST; PROTEIN FUNCTION; PROTEIN HYDROLYSIS;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; CANNABINOIDS; CANNABIS; CERCOPITHECUS AETHIOPS; COS CELLS; ENDOCANNABINOIDS; GLYCERIDES; HEK293 CELLS; HUMANS; LIPOPROTEIN LIPASE; MONOACYLGLYCEROL LIPASES; PALMITIC ACIDS; PLANT EXTRACTS; POLYUNSATURATED ALKAMIDES; RATS; TRANSIENT RECEPTOR POTENTIAL CHANNELS;

EID: 79960328574     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01166.x     Document Type: Article

References (79)

1. Akopian AN, Ruparel NB, Patwardhan A, Hargreaves KM, (2008). Cannabinoids desensitize capsaicin and mustard oil responses in sensory neurons via TRPA1 activation. J Neurosci 28: 1064-1075. (Pubitemid 351186337)
2. Akopian AN, Ruparel NB, Jeske NA, Patwardhan A, Hargreaves KM, (2009). Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. Trends Pharmacol Sci 30: 79-84.
3. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al,. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845-852. (Pubitemid 33016156)
4. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, et al,. (2003). Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signalling in the brain. J Cell Biol 163: 463-468. (Pubitemid 37429860)
5. Bisogno T, Cascio MG, Saha B, Mahadevan A, Urbani P, Minassi A, et al,. (2006). Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 1761: 205-212.
6. Bisogno T, Burston JJ, Rai R, Allarà M, Saha B, Mahadevan A, et al,. (2009). Synthesis and pharmacological activity of a potent inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol. ChemMedChem 4: 946-950.
7. 9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol 160: 677-687.
8. Campos AC, Guimarães FS, (2008). Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology 199: 223-230.
9. Capasso R, Borrelli F, Aviello G, Romano B, Scalisi C, Capasso F, et al,. (2008). Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br J Pharmacol 154: 1001-1008. (Pubitemid 351915071)
10. Carrier EJ, Auchampach JA, Hillard CJ, (2006). Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 103: 7895-7900.
11. Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG, (2010). Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br J Pharmacol 159: 129-141.
12. Comelli F, Giagnoni G, Bettoni I, Colleoni M, Costa B, (2007). The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation. Br J Pharmacol 152: 787-794. (Pubitemid 350034978)
13. Costa B, Colleoni M, Conti S, Parolaro D, Franke C, Trovato AE, et al,. (2004). Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol 369: 294-299. (Pubitemid 38372934)
14. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M, (2007). The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 556: 75-83. (Pubitemid 46074009)
15. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB, (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384: 83-87. (Pubitemid 26374593)
16. De Petrocellis L, Di Marzo V, (2010). Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J Neuroimmune Pharmacol 5: 103-121.
17. De Petrocellis L, Starowicz K, Schiano-Moriello A, Vivese M, Orlando P, Di Marzo V, (2007). Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. Exp Cell Res 313: 1911-1920. (Pubitemid 46661844)
18. De Petrocellis L, Vellani V, Schiano-Moriello A, Marini P, Magherini PC, Orlando P, et al,. (2008). Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther 325: 1007-1015. (Pubitemid 351724325)
19. Delong GT, Wolf CE, Poklis A, Lichtman AH, (2010). Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Delta(9)-tetrahydrocannabinol. Drug Alcohol Depend 112: 126-133.
20. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, et al,. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949. (Pubitemid 23026736)
21. Di Marzo V, Després JP, (2009). CB1 antagonists for obesity-what lessons have we learned from rimonabant? Nat Rev Endocrinol 5: 633-638.
22. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, et al,. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372: 686-691.
23. Di Marzo V, De Petrocellis L, Bisogno T, (2005). The biosynthesis, fate and pharmacological properties of endocannabinoids. In:, Pertwee RG, (ed.). Cannabinoids. Handbook of Experimental Pharmacology, Vol. 168. Springer-Verlag: Heidelberg, pp. 147-185.
24. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, et al,. (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99: 10819-10824.
25. 2+ elevations in hippocampal cells. Neuropharmacology 50: 621-631.
26. ElSohly MA, Slade D, (2005). Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 78: 539-548. (Pubitemid 41653504)
27. Gaoni Y, Mechoulam R, (1964). Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86: 1646-1647.
28. García-Arencibia M, González S, de Lago E, Ramos JA, Mechoulam R, Fernández-Ruiz J, (2007). Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 1134: 162-170. (Pubitemid 46135535)
29. Giudice ED, Rinaldi L, Passarotto M, Facchinetti F, D'Arrigo A, Guiotto A, et al,. (2007). Cannabidiol, unlike synthetic cannabinoids, triggers activation of RBL-2H3 mast cells. J Leukoc Biol 81: 1512-1522. (Pubitemid 46827974)
30. Gong J-P, Onaivi ES, Ishiguro H, Liu Q-R, Tagliaferro PA, Brusco A, et al,. (2006). Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071: 10-23. (Pubitemid 43255471)
31. Guindon J, Desroches J, Beaulieu P, (2007). The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br J Pharmacol 150: 693-701. (Pubitemid 46440208)
32. 9-tetrahydrocannabinol: interactions relative to lethality, hypothermia and hexobarbital hypnosis. Gen Pharmacol 12: 357-362. (Pubitemid 11053512)
33. 9- tetrahydrocannabinol via CB(1) receptor-dependent mechanism. Brain Res 1188: 157-164. (Pubitemid 350296050)
34. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, et al,. (2005). An endocannabinoid mechanism for stress-induced analgesia. Nature 435: 1108-1112. (Pubitemid 40910518)
35. Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L, (2009). Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neurosci Ther 15: 65-75.
36. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R, (2009). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30: 515-527.
37. Jordt SE, Bautista DM, Chuang HH, McKemy DD, Zygmunt PM, Högestätt ED, et al,. (2004). Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 427: 260-265. (Pubitemid 38112043)
38. King AR, Dotsey EY, Lodola A, Jung KM, Ghomian A, Qiu Y, et al,. (2009). Discovery of potent and reversible monoacylglycerol lipase inhibitors. Chem Biol 16: 1045-1052.
39. Levine JD, Alessandri-Haber N, (2007). TRP channels: targets for the relief of pain. Biochim Biophys Acta 1772: 989-1003. (Pubitemid 47176368)
40. Ligresti A, Morera E, Van Der Stelt M, Monory K, Lutz B, Ortar G, et al,. (2004). Further evidence for the existence of a specific process for the membrane transport of anandamide. Biochem J 380: 265-272. (Pubitemid 38725751)
41. Ligresti A, Schiano-Moriello A, Starowicz K, Matias I, Pisanti S, De Petrocellis L, et al,. (2006). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318: 1375-1387. (Pubitemid 44268348)
42. Ligresti A, De Petrocellis L, Hernán Pérez de la Ossa D, Aberturas R, Cristino L, Schiano-Moriello A, et al,. (2010). Exploiting nanotechnologies and TRPV1 channels to investigate the putative anandamide membrane transporter. PloS One 5: e10239.
43. McNamara CR, Mandel-Brehm J, Bautista DM, Siemens J, Deranian KL, Zhao M, et al,. (2007). TRPA1 mediates formalin-induced pain. Proc Natl Acad Sci USA 104: 13525-13530. (Pubitemid 47293978)
44. Magen I, Avraham Y, Ackerman Z, Vorobiev L, Mechoulam R, Berry EM, (2010). Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT1A receptor activation. Br J Pharmacol 159: 950-957.
45. 9- tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol Cancer Ther 9: 180-189.
46. Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D, (2004). Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308: 838-845. (Pubitemid 38263956)
47. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI, (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
48. Mechoulam R, (2000). Looking back at Cannabis research. Curr Pharm Des 6: 1313-1322.
49. Mechoulam R, Shvo Y, (1963). Hashish-I: the structure of cannabidiol. Tetrahedron 19: 2073-2078.
50. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al,. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83-90.
51. Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, et al,. (2010). Potency trends of Δ(9) -THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 55: 1209-1217.
52. Monet M, Gkika D, Lehen'kyi V, Pourtier A, Vanden Abeele F, Bidaux G, et al,. (2009). Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. Biochim Biophys Acta 1793: 528-539.
53. Morita A, Iwasaki Y, Kobata K, Iida T, Higashi T, Oda K, et al,. (2006). Lipophilicity of capsaicinoids and capsinoids influences the multiple activation process of rat TRPV1. Life Sci 79: 2303-2310. (Pubitemid 44666065)
54. Munro S, Thomas KL, Abu SM, (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65. (Pubitemid 23305569)
55. Neeper MP, Liu Y, Hutchinson TL, Wang Y, Flores CM, Qin N, (2007). Activation properties of heterologously expressed mammalian TRPV2: evidence for species dependence. J Biol Chem 282: 15894-15902. (Pubitemid 47093309)
56. Pan H, Mukhopadhyay P, Rajesh M, Patel V, Mukhopadhyay B, Gao B, et al,. (2009). Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J Pharmacol Exp Ther 328: 708-714.
57. Pertwee RG, (2004). The pharmacology and therapeutic potential of cannabidiol. In:, Di Marzo V, (ed.). Cannabinoids. Kluwer Academic/Plenum Publishers: London, pp. 32-83.
58. 9-tetrahydrocannabivarin. Br J Pharmacol 153: 199-215.
59. Petrosino S, Iuvone T, Di Marzo V, (2010). N-palmitoyl-ethanolamine: biochemistry and new therapeutic opportunities. Biochimie 92: 724-727.
60. Petrus M, Peier AM, Bandell M, Hwang SW, Huynh T, Olney N, et al,. (2007). A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition. Mol Pain 3: 40.
61. Qin N, Neeper MP, Liu Y, Hutchinson TL, Lubin ML, Flores CM, (2008). TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci 28: 6231-6238.
62. Resstel LB, Tavares RF, Lisboa SF, Joca SR, Corrêa FM, Guimarães FS, (2009). 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol 156: 181-188.
63. Russo E, Guy GW, (2006). A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66: 234-246. (Pubitemid 41773895)
64. Russo EB, Burnett A, Hall B, Parker KK, (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30: 1037-1043. (Pubitemid 41570039)
65. 2+ levels. J Neurosci 29: 2053-2063.
66. Saturnino C, Petrosino S, Ligresti A, Palladino C, De Martino G, Bisogno T, et al,. (2010). Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase. Bioorg Med Chem Lett 20: 1210-1213.
67. 9-tetrahydrocannabinol, hydrocortisone and aspirin in various rat paw edema models. Life Sci 15: 251-260.
68. Solorzano C, Zhu C, Battista N, Astarita G, Lodola A, Rivara S, et al,. (2009). Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci USA 106: 20966-20971.
69. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al,. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Comm 215: 89-97.
70. 9- tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146: 917-926. (Pubitemid 41722163)
71. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG, (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 150: 613-623. (Pubitemid 46355558)
72. Turner CE, Elsohly MA, (1981). Biological activity of cannabichromene, its homologs and isomers. J Clin Pharmacol 21: 283S-291S.
73. Ueda N, Yamanaka K, Yamamoto S, (2001). Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J Biol Chem 276: 35552-355527.
74. Ueda N, Tsuboi K, Uyama T, (2010). N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA). Prog Lipid Res 49: 299-315.
75. Ursu D, Knopp K, Beattie RE, Liu B, Sher E, (2010). Pungency of TRPV1 agonists is directly correlated with kinetics of receptor activation and lipophilicity. Eur J Pharmacol 641: 114-122.
76. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al,. (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310: 329-332. (Pubitemid 41457202)
77. Varvel SA, Wiley JL, Yang R, Bridgen DT, Long K, Lichtman AH, et al,. (2006). Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology 186: 226-234. (Pubitemid 43727340)
78. Watanabe K, Ogi H, Nakamura S, Kayano Y, Matsunaga T, Yoshimura H, et al,. (1998). Distribution and characterization of anandamide amidohydrolase in mouse brain and liver. Life Sci 62: 1223-1229. (Pubitemid 28153505)
79. Yang KH, Galadari S, Isaev D, Petroianu G, Shippenberg TS, Oz M, (2010). The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes. J Pharmacol Exp Ther 333: 547-554. (Pubitemid 350005116)